Clinical trials: Cholesterol; Metabolic Disorder
Hyperlipidemia
A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
Researchers designed a study medicine called enlicitide to lower low-density lipoprotein cholesterol (LDL-C). In this study, researchers want to learn about giving enlicitide with another medicine called rosuvastatin.
- Trial name
- NCT07216482
- Testing
- Enlicitide, Rosuvastatin
- Where
- 87 sites in United States, Argentina and 9 more
- Volunteers
- 996 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypercholesterolemia
Flax Lignans and Heart Health
Purpose: To demonstrate the efficacy of Beneflax™ flaxseed lignan (SDG) concentrate to lower serum cholesterol levels. Background: Flaxseed has been studied for various health benefits in humans, including prostate health…
- Trial name
- ISULignan (NCT01314586)
- Testing
- secoisolariciresinol diglucoside-containing extract of flaxseed
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Iowa State University
Dyslipidemia
An Observational Study Investigating the Change in Blood Cholesterol With Mevalotin® Tablet Administration in Korean Menopausal Women Aged 50 Years or More Who Require Treatment of Dyslipidemia
This study will investigate the efficacy and safety based on the observation of the blood cholesterol change with Mevalotin® Tablet administration in Korean menopausal women aged 50 years or more who require treatment of…
- Trial name
- NCT05120895
- Testing
- Mevalotin
- Where
- 58 sites in South Korea
- Volunteers
- 3,060 people
- Sponsor
- Daiichi Sankyo
Hyperlipidemia
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2
The primary objective was to evaluate the effect of 12 weeks of subcutaneous (SC) evolocumab every 2 weeks (Q2W) and monthly (QM), compared with ezetimibe, on percent change from baseline in low-density lipoprotein cholesterol…
- Trial name
- GAUSS-2 (NCT01763905)
- Testing
- Evolocumab, Ezetimibe
- Where
- 58 sites in United States, Australia and 12 more
- Volunteers
- 307 people
- Sponsor
- Amgen
Healthy
Study of no Pharmacokinetic Interaction Between Rosuvastatin 20mg and Ezetimibe10mg, Fixed Dose vs Individual Components
Monocentric study of no pharmacokinetic interaction between rosuvastatin 20 mg and ezetimibe 10 mg. An open design, randomized, single dose with three periods, six sequences and crossed, in healthy volunteers with fasting…
- Trial name
- NCT04895059
- Testing
- Rosuvastatin (20mg) /Ezetimibe (10mg) in fixed dose, Rosuvastatin 20mg, Ezetimibe 10mg
- Where
- Mexico
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Laboratorios Silanes S.A. de C.V.
Lipoprotein Disorder
A Study of DII235 in Adults With Elevated Lipoprotein(a)
The main purpose of this study is to determine the safety and efficacy of DII235 in adults with elevated lipoprotein(a).
- Trial name
- NCT07235046
- Testing
- DII235, Saline
- Where
- 63 sites in United States, China and 2 more
- Volunteers
- 234 people
- Sponsor
- Novartis Pharmaceuticals
Heart Diseases, Metabolism, Inborn Errors
Higher-Dose Ezetimibe to Treat Homozygous Sitosterolemia
This study will test the safety and effectiveness of 40 mg of ezetimibe (Zetia ) daily in lowering blood levels of cholesterol and of the plant sterols sitosterol and campesterol in patients with homozygous sitosterolemia, an…
- Trial name
- NCT00099996
- Testing
- SCH-58235, Ezetimibe
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Dyslipidemia Associated With Type II Diabetes Mellitus
Moderate-intensity Statin vs. Individualized LDL-C Target-based Therapy in Older Adults With Type 2 Diabetes (iTARGET-Elderly Study)
Statins are the cornerstone of cardiovascular disease (CVD) prevention through the lowering of low-density lipoprotein cholesterol (LDL-C).
- Trial name
- NCT07359105
- Testing
- Moderate-intensity statin monotherapy, Ezetimibe or ezetimibe-statin combination therapy
- Where
- 2 sites in South Korea
- Volunteers
- 2,186 people
- Sponsor
- Sin Gon Kim
Cardiovascular Disease, Diabetes Mellitus
Living With Statins - The Impact of Cholesterol Lowering Drugs on Health, Lifestyle and Well-being
Background Statins are cholesterol lowering drugs that are prescribed to lower the risk of cardio-vascular diseases. The use of statins has increased markedly and it is now one of the most prescribed drugs in the world.
- Trial name
- LIFESTAT (NCT02255682)
- Testing
- Simvastatin, Q10
- Where
- Denmark
- Volunteers
- 35 people
- Sponsor
- University of Copenhagen
Hypercholesterolemia
Effect of Ezetimibe Treatment on Low-density Lipoprotein Cholesterol (LDL-C) Levels in Participants With Coronary Heart Disease (CHD) Already Treated With a Statin (MK-0653A-205 AM1)
This non-interventional longitudinal study is a follow-up of the Austrian Cholesterol Screening and Treatment project (ACT I), which assessed the cholesterol status, including achievement of the target levels applicable at that…
- Trial name
- ACT II (NCT01381679)
- Testing
- Ezetimibe
- Volunteers
- 1,682 people
- Sponsor
- Organon and Co
Metabolic Syndrome, Hyperlipidemia
The Effects of ProAlgaZyme on HDL Cholesterol in Individuals With Metabolic Syndrome
The purpose of this study is to determine the effectiveness of ProAlgaZyme in increasing levels of HDL 'good' cholesterol and decreasing total cholesterol and C-reactive protein in patients with Metabolic Syndrome.
- Trial name
- NCT00518960
- Testing
- ProAlgaZyme
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Health Enhancement Products, Inc.
Hyperlipidemia
A Study to Evaluate the Lipid Regulating Effects of TRIA-662
The purpose of this study is to determine the effectiveness and safety of TRIA-662 (also known as 1-MNA) in treating elevated triglyceride levels in patients not receiving lipid lowering treatment.
- Trial name
- NCT00758303
- Testing
- Low Dose TRIA-662, High Dose TRIA-662
- Volunteers
- 211 people
- Sponsor
- Cortria Corporation
Lysosomal Acid Lipase Deficiency, Wolman Disease
A Retrospective Natural History Study of Patients With Lysosomal Acid Lipase Deficiency/Wolman Phenotype
This is a Natural History study to characterize key aspects of the clinical course of lysosomal acid lipase (LAL) deficiency/Wolman phenotype in patients.
- Trial name
- NCT01358370
- Where
- 14 sites in United States, Canada and 3 more
- Volunteers
- 40 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Cardiovascular Disease, Diabetes
The Effects of Natural Versus Man-Made Trans Fatty Acids on Lipoprotein Profiles: A Pilot Study
The purpose of this study is to test the effects of natural vs. man-made trans fatty acids (trans fats) on blood cholesterol.
- Conditions
- Cardiovascular Disease, Diabetes, Dyslipidemia
- Trial name
- NCT00535886
- Testing
- Man-made Trans FA, Natural Trans FA, Oleic Acid
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- UCSF Benioff Children's Hospital Oakland
Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia
Patterns of Inclisiran Use in the Real World: An Analysis of US Databases
This was a retrospective observational cohort study of patients who initiated inclisiran, alirocumab, or evolocumab in a real-world setting in the United States.
- Trial name
- NCT07023445
- Where
- United States
- Volunteers
- 37,688 people
- Sponsor
- Novartis Pharmaceuticals
Hypercholesterolemia
Study of Efficacy and Safety of Inclisiran in Asian Participants With Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD High Risk and Elevated Low Density Lipoprotein Cholesterol (LDL-C)
A multicenter study to evaluate safety and efficacy of inclisiran in Asian patients with ASCVD or ASCVD high risk and elevated LDL-C
- Trial name
- NCT04765657
- Testing
- inclisiran sodium
- Where
- 45 sites in China, Singapore and 2 more
- Volunteers
- 345 people
- Sponsor
- Novartis Pharmaceuticals
Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk
The purpose of this study is to see if bemedoic acid (ETC-1002) is effective versus placebo in patients with high cardiovascular risk and elevated LDL cholesterol not adequately controlled by their current therapy.
- Trial name
- CLEAR Wisdom (NCT02991118)
- Testing
- bempedoic acid
- Where
- 2 sites in United States
- Volunteers
- 779 people
- Sponsor
- Esperion Therapeutics, Inc.
Diabetes Mellitus, Hypercholessterolemia
Korean AMADEUS Study
Because Diabetes Mellitus is one of the major risk factors for CV disease and lots of related evidences have been published including CARDS study that showed definite benefit of statin treatment in DM patients and influenced ADA…
- Trial name
- NCT01239849
- Testing
- Atorvastatin, 10mg, 20mg, 40mg
- Where
- South Korea
- Volunteers
- 500 people
- Sponsor
- The Catholic University of Korea
Dyslipidemias, Hypercholesterolemia
Serum Cholesterol Reduction Efficacy of Biscuit With Plant Stanol Ester
Efficacy of plant stanols as esters on LDL-cholesterol reduction is well documented. LDL-cholesterol lowering efficacy of the ingredient in a biscuit (providing 2 g plant stanols as esters per day) is less well known.
- Conditions
- Dyslipidemias, Hypercholesterolemia, Hyperlipidemias
- Trial name
- NCT02331043
- Testing
- Plant stanol ester
- Where
- Thailand
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Raisio Group
Hypercholesterolemia
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C
The purpose of this study is to determine if triplet therapy with bempedoic acid (ETC-1002) 180mg, ezetimibe 10mg, and atorvastatin 20mg is effective and safe versus placebo in patients with elevated LDL cholesterol.
- Trial name
- NCT03051100
- Testing
- Bempedoic acid 180mg, Ezetimibe 10mg, Atorvastatin 20mg
- Where
- 11 sites in United States
- Volunteers
- 63 people
- Sponsor
- Esperion Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.